Search

Your search keyword '"Grand'Maison, F"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Grand'Maison, F" Remove constraint Author: "Grand'Maison, F" Topic neurology (clinical) Remove constraint Topic: neurology (clinical)
28 results on '"Grand'Maison, F"'

Search Results

1. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

2. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

3. 250 mu g or 500 mu g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

4. Health-related quality of life in multiple sclerosis: Effects of natalizumab

5. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

6. Determinants of therapeutic lag in multiple sclerosis

7. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

8. Timing of high-efficacy therapy for multiple sclerosis:a retrospective observational cohort study

9. Early clinical markers of aggressive multiple sclerosis

10. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

11. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

12. Risk of secondary progressive multiple sclerosis: A longitudinal study

13. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

14. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

15. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

16. BREMSO: a simple score to predict early the natural course of multiple sclerosis

17. Risk of relapse phenotype recurrence in multiple sclerosis

18. Fingolimod after natalizumab and the risk of short-term relapse

19. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

20. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

21. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

22. Predictors of disability worsening in clinically isolated syndrome

23. Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

24. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

25. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

26. Fluctuations of MS births and UV-light exposure

27. Increasing age at disability milestones among MS patients in the MSBase Registry

28. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Catalog

Books, media, physical & digital resources